Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label infarct growth. Show all posts
Showing posts with label infarct growth. Show all posts

Saturday, August 9, 2025

Oxygen Extraction Fraction on Baseline MRI Predicts Infarction Growth in Successfully Reperfused Patients

 WHAT WILL PREVENT INFARCTION GROWTH? WHOM will do the research to solve that? Nothing will occur, we have NO leadership and NO strategy in stroke, so your children and grandchildren will still be screwed when they have strokes!

LEADERS would look at this and say; 'Let's do the research to solve the problem! You're uselessly predicting a problem; NOT SOLVING IT! 

But there are NO FUNCTIONING BRAIN CELLS IN THE STROKE MEDICAL WORLD!

Oxygen Extraction Fraction on Baseline MRI Predicts Infarction Growth in Successfully Reperfused Patients


Asghariahmadabad MD, Ameera MD, Metanat MD, https://orcid.org/0000-0003-2905-4080Tavakkol MD  https://orcid.org/0000-0003-2869-8087, Bahr-Hosseini MD https://orcid.org/0000-0003-3049-4542,  Viktor Szeder MD, PhD https://orcid.org/0000-0003-0703-8258, Geoffrey P. Colby MD, PhD https://orcid.org/0000-0002-3376-0933, Show All … , and Kambiz Nael, MD https://orcid.org/0000-0002-4194-9488 kambiznael@gmail.com
Author Info & AffiliationsInformation & Authors
  • Metrics & Citations
  • Get Access
  • References
  • Figures
  • Abstract

    BACKGROUND:
    In patients with acute ischemic stroke, infarct growth occurs despite successful reperfusion. Oxygen extraction fraction (OEF) has shown promising results in evaluating ischemic tissue viability and can now be quantified from routinely performed dynamic susceptibility contrast perfusion. We aimed to determine the association of OEF alterations within the ischemic tissue on pretreatment magnetic resonance imaging and infarct growth in patients who underwent successful reperfusion.

    METHODS:

    In this retrospective cohort study from the University of California, Los Angeles, between 2015 and 2020, patients were included if they had anterior circulation large vessel occlusion, achieved successful reperfusion (Thrombolysis in Cerebral Infarction ≥2b), had pretreatment dynamic susceptibility contrast perfusion and posttreatment magnetic resonance imaging within 48 hours from reperfusion. Dynamic susceptibility contrast-derived OEF values were quantified from the segmented ischemic core (apparent diffusion coefficient ≤620×10−6 mm2/s) and penumbra tissue (time-to-maximum [Tmax] >6 s) on pretreatment magnetic resonance imaging and normalized to contralateral hemisphere (relative oxygen extraction fraction [OEFr]). Primary outcome was substantial infarct growth ≥10 mL, and secondary outcomes were continuous measures of infarct growth volume and penumbra-to-infarct conversion ratio. The associations between baseline clinical and imaging variables, including OEFr and outcome measures, were tested by multivariate and regression analysis.

    RESULTS:

    Among 89 patients who met inclusion criteria, 33 (37%) patients had infarct growth ≥10 mL. Patients with infarct growth had significantly (P<0.0001) lower penumbra-OEFr values compared with those without infarct growth. There was significant association between penumbra OEFr and infarct growth (β=−2.9 [95% CI, −5.0 to −0.8]; P=0.007) and similarly for penumbra-to-infarct conversion ratio (β=−10.4 [95% CI, −19.6 to −1.2]; P=0.028).

    CONCLUSIONS:

    Our results showed penumbra-OEFr is a promising imaging biomarker for predicting infarct growth in acute ischemic stroke following successful reperfusion. Although elevation of penumbra-OEFr is protective, patients with lower penumbra-OEFr values sustained further ischemic injury and infarct growth.

    Graphical Abstract

    Get full access to this article

    View all available purchase options and get full access to this article.

    Thursday, August 7, 2025

    Oxygen Extraction Fraction on Baseline MRI Predicts Infarction Growth in Successfully Reperfused Patients

     

    What other protocols is your doctor using to significantly improve oxygen delivery immediately post stroke? The first hours and days? NOTHING? Then you DON'T have a functioning stroke doctor, do you?

    Biomarkers DO NOTHING FOR RECOVERY! Or don't you know that?

    Maybe these, why isn't your incompetent doctor already delivering these to you?

    cerebral blood flow (29 posts to July 2016)

    Cerebral blood flow autoregulation (1 post to July 2021)

    Cerebral Blood Flow Velocity (1 post to Febraury 2020)

    cortical oxygenation (1 post to November 2020)

    oxygen delivery (20 posts to January 2020)

    oxygen uptake (5 posts to August 2013)

    Normobaric oxygen (10 posts to January 2020)

  • brain blood flow (3 posts to April 2019)

  •  Oh, your incompetent doctor doesn't have any and doesn't fucking care about learning better ways to get you recovered! Well, fire them! PREDICTING DAMAGE DOES NOTHING!

    The latest here:

    Oxygen Extraction Fraction on Baseline MRI Predicts Infarction Growth in Successfully Reperfused Patients


    Mona Asghariahmadabad M, Ameera Ismail MD,  Pouya Metanat MD,  https://orcid.org/0000-0003-2905-4080, Elham Tavakkol MD  https://orcid.org/0000-0003-2869-8087 Mersedeh Bahr-Hosseini MD https://orcid.org/0000-0003-3049-4542, Viktor Szeder MD, PhD https://orcid.org/0000-0003-0703-8258, Geoffrey P. Colby MD, PhD https://orcid.org/0000-0002-3376-0933 Show All …
     , and Kambiz Nael, MD https://orcid.org/0000-0002-4194-9488 kambiznael@gmail.com Author Info & AffiliationsNew onlineGet Access

    Abstract

    BACKGROUND:In patients with acute ischemic stroke, infarct growth occurs despite successful reperfusion. Oxygen extraction fraction (OEF) has shown promising results in evaluating ischemic tissue viability and can now be quantified from routinely performed dynamic susceptibility contrast perfusion. We aimed to determine the association of OEF alterations within the ischemic tissue on pretreatment magnetic resonance imaging and infarct growth in patients who underwent successful reperfusion.METHODS:
    In this retrospective cohort study from the University of California, Los Angeles, between 2015 and 2020, patients were included if they had anterior circulation large vessel occlusion, achieved successful reperfusion (Thrombolysis in Cerebral Infarction ≥2b), had pretreatment dynamic susceptibility contrast perfusion and posttreatment magnetic resonance imaging within 48 hours from reperfusion. Dynamic susceptibility contrast-derived OEF values were quantified from the segmented ischemic core (apparent diffusion coefficient ≤620×10−6 mm2/s) and penumbra tissue (time-to-maximum [Tmax] >6 s) on pretreatment magnetic resonance imaging and normalized to contralateral hemisphere (relative oxygen extraction fraction [OEFr]). Primary outcome was substantial infarct growth ≥10 mL, and secondary outcomes were continuous measures of infarct growth volume and penumbra-to-infarct conversion ratio. The associations between baseline clinical and imaging variables, including OEFr and outcome measures, were tested by multivariate and regression analysis.

    RESULTS:

    Among 89 patients who met inclusion criteria, 33 (37%) patients had infarct growth ≥10 mL. Patients with infarct growth had significantly (P<0.0001) lower penumbra-OEFr values compared with those without infarct growth. There was significant association between penumbra OEFr and infarct growth (β=−2.9 [95% CI, −5.0 to −0.8]; P=0.007) and similarly for penumbra-to-infarct conversion ratio (β=−10.4 [95% CI, −19.6 to −1.2]; P=0.028).

    CONCLUSIONS:

    Our results showed penumbra-OEFr is a promising imaging biomarker for predicting infarct growth in acute ischemic stroke following successful reperfusion. Although elevation of penumbra-OEFr is protective, patients with lower penumbra-OEFr values sustained further ischemic injury and infarct growth.

    Graphical Abstract


    Saturday, February 8, 2025

    Revalesio announces new analyses from Phase 2 RESCUE study assessing RNS60 in acute ischaemic stroke

     You'll have to ask your competent? doctor which of the 5 causes of the neuronal cascade of death in the first week is being addressed! 

    I wish they had used the proper term; penumbra, and specified exactly how many millions of neurons were saved.

    I consider the Rankin scale useless, not objective except for #6, dead?

    NIHSS and the Berthel Index ARE NOT DAMAGE DIAGNOSES, they do not give you the 3d location of your dead and damaged neurons. In my opinion, they are FUCKING WORTHLESS to getting you recovered! 

    The latest here:

    Revalesio announces new analyses from Phase 2 RESCUE study assessing RNS60 in acute ischaemic stroke

    Revalesio has announced new analyses of the completed Phase 2 RESCUE clinical trial evaluating its drug candidate RNS60 in acute ischaemic stroke that demonstrate a nominally significant lowering of infarct growth in patients treated less than 12 hours from last known well. The lowering of infarct growth correlated with clinically meaningful improvements in several functional stroke measures for assessing a patient’s recovery(None of which are worth a damn, about helping you get recovered!), including the modified Rankin scale (mRS), Barthel index (BI), and National Institutes of Health stroke scale (NIHSS), the company claims in a recent press release.

    These results were delivered during an oral presentation at the ongoing International Stroke Conference (ISC; 5–7 February, Los Angeles, USA).

    “This analysis of the RESCUE trial adds further information regarding the beneficial effects of RNS60, confirming that it has favourable effects on MRI [magnetic resonance imaging]-confirmed ischaemic lesion growth that translated into improved clinical outcomes,” said former World Stroke Organization (WSO) president Marc Fisher (Beth Israel Deaconess Medical Center, Boston, USA). “These are exciting results that suggest that RNS60 should be evaluated in a large Phase 3 clinical trial that will hopefully confirm its benefits and lead to approval as the first therapeutic agent in decades to demonstrate significant efficacy in improving outcomes for acute ischaemic stroke patients.”

    In RESCUE—a multicentre, double-blinded, placebo-controlled, randomised Phase 2 clinical trial—Revalesio evaluated the safety and initial efficacy of RNS60. Eighty-two participants with acute ischaemic stroke eligible for endovascular therapy (EVT) were enrolled and received either intravenous RNS60 0.5mL/kg/h (low dose), RNS60 1mL/kg/h (high dose), or placebo, starting before completion of EVT and continuing for 48 hours.

    The trial had two primary endpoints: safety and mortality. Secondary endpoints for the study assessed disability based on mRS scores, changes in the size of the stroke measured via MRI at 48 hours, and additional standard stroke scales like BI and NIHSS.

    Highlights from the oral presentation—given by Revalesio’s acting chief medical officer Jordan Dubow on 5 February at ISC 2025—are as follows:

    • The high dose of RNS60 significantly lowered infarct growth by 50% (nominal p<0.05) when compared to placebo, based on imaging performed at approximately 48 hours compared to immediately post-EVT, both in patients treated within 12 hours and 24 hours of last known well
    • The high dose of RNS60 was also numerically better than placebo for each prespecified functional endpoint at day 90 (mRS, with 72% of subjects on high-dose RNS60 being independent [mRS 0–2] at day 90 compared to 37% on placebo; BI, with 72% of subjects on high-dose RNS60 returning to normal activities of daily living [BI³ 95] compared to 37% on placebo; and patient health status as measured by the EQ-5D-5L index, with 1 being ideal, which was 0.79 for RNS60 subjects and 0.57 for placebo)
    • RNS60 was safe and well tolerated

    “As the number-one cause of disability worldwide, the impact of stroke is staggering, accounting for US$721 billion annually to the global healthcare system,” said Bert van den Bergh, Revalesio’s executive chairman of the board of directors. “Additionally, more than 80% of patients in the USA have no treatment options following a stroke, underscoring the significant need for new and effective treatment options. These highly encouraging results further demonstrate the potential of RNS60 to greatly reduce the likelihood of disability in patients following a stroke, and we plan to advance RNS60 into a Phase 3 clinical trial in order to bring this promising therapy to patients.”

    Initial topline results from the RESCUE Phase 2 study—which evaluated patients who were 24 hours from last known well, and saw RNS60 meet its safety- and mortality-related endpoints—were presented as a late-breaking oral presentation at last year’s ISC (7–9 February 2024, Phoenix, USA).

    Monday, October 11, 2021

    Prediction of Stroke Infarct Growth Rates by Baseline Perfusion Imaging

    Survivors don't give a shit about your useless predictions of damage. You're supposed to prevent such damage. GET THERE!

    Prediction of Stroke Infarct Growth Rates by Baseline Perfusion Imaging

     
    Originally publishedhttps://doi.org/10.1161/STROKEAHA.121.034444Stroke. ;0:STROKEAHA.121.034444

    Background and Purpose:

    Computed tomography perfusion imaging allows estimation of tissue status in patients with acute ischemic stroke. We aimed to improve prediction of the final infarct and individual infarct growth rates using a deep learning approach.

    Methods:

    We trained a deep neural network to predict the final infarct volume in patients with acute stroke presenting with large vessel occlusions based on the native computed tomography perfusion images, time to reperfusion and reperfusion status in a derivation cohort (MR CLEAN trial [Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands]). The model was internally validated in a 5-fold cross-validation and externally in an independent dataset (CRISP study [CT Perfusion to Predict Response to Recanalization in Ischemic Stroke Project]). We calculated the mean absolute difference between the predictions of the deep learning model and the final infarct volume versus the mean absolute difference between computed tomography perfusion imaging processing by RAPID software (iSchemaView, Menlo Park, CA) and the final infarct volume. Next, we determined infarct growth rates for every patient.

    Results:

    We included 127 patients from the MR CLEAN (derivation) and 101 patients of the CRISP study (validation). The deep learning model improved final infarct volume prediction compared with the RAPID software in both the derivation, mean absolute difference 34.5 versus 52.4 mL, and validation cohort, 41.2 versus 52.4 mL (P<0.01). We obtained individual infarct growth rates enabling the estimation of final infarct volume based on time and grade of reperfusion.

    Conclusions:

    We validated a deep learning-based method which improved final infarct volume estimations compared with classic computed tomography perfusion imaging processing. In addition, the deep learning model predicted individual infarct growth rates which could enable the introduction of tissue clocks during the management of acute stroke.